FDA Drug Recalls

Recalls / Class II

Class IID-0518-2025

Product

Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 90-count bottle, Rx Only, Manufactured for: Accord Healthcare, Inc., Raleigh, NC 27617, Manufactured by: Intas Pharmaceuticals Limited, Camp Road, Selaqui, Dehradun-248 197, India, NDC 16729-447-15

Brand name
Levothyroxine Sodium
Generic name
Levothyroxine Sodium
Active ingredient
Levothyroxine Sodium
Route
Oral
NDCs
16729-447, 16729-458, 16729-448, 16729-449, 16729-451, 16729-450, 16729-452, 16729-453, 16729-454, 16729-455 +2 more
FDA application
ANDA212399
Affected lot / code info
Lot #D2300325, Exp Date: 01/31/2026; Lot #D2400536, Exp Date: 02/28/2026

Why it was recalled

Subpotent Drug: Assay below the approved specification

Recalling firm

Firm
ACCORD HEALTHCARE, INC.
Manufacturer
Accord Healthcare Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
8041 Arco Corporate Dr Ste 200, N/A, Raleigh, North Carolina 27617-2010

Distribution

Quantity
82,159 bottles
Distribution pattern
Nationwide in the USA

Timeline

Recall initiated
2025-06-20
FDA classified
2025-07-14
Posted by FDA
2025-07-23
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0518-2025. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.